Business

Lyfebulb-Novo Nordisk Innovation Award 2017

The Lyfebulb-Novo Nordisk Innovation Summit 2017 will recognize and empower international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management. Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. The aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.

Gene variant activity is surprisingly variable between tissues

Every gene in (almost) every cell of the body is present in two variants - so called alleles: one is deriving from the mother, the other one from the father. In most cases both alleles are active and transcribed by the cells into an RNA message. However, for a few genes, only one allele is expressed, while the other one is silenced.

Bayer receives EU approval for Stivarga® (Regorafenib) for the second-line systemic treatment of liver cancer

Bayer today announced the European Commission (EC) has granted marketing authorization for Stivarga® (regorafenib) for the treatment of adult patients with HCC who have been previously treated with Nexavar® (sorafenib). Stivarga is the first and only treatment that has demonstrated a significant improvement in overall survival (OS) in second-line HCC.

Titanium dioxide nanoparticles can exacerbate colitis

Titanium dioxide, one of the most-produced nanoparticles worldwide, is being used increasingly in foodstuffs. When intestinal cells absorb titanium dioxide particles, this leads to increased inflammation and damage to the intestinal mucosa in mice with colitis. Researchers at the University of Zurich recommend that patients with colitis should avoid food containing titanium dioxide particles.

Kyntheum approved in the EU for the treatment of adults with moderate-to-severe plaque psoriasis

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that its partner LEO Pharma has been granted full marketing authorisation in all 28 EU member countries plus Iceland, Liechtenstein and Norway for Kyntheum (brodalumab), a new biologic medicine developed for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.

Merck Biopharma Innovation Cup 2017

Merck, a leading science and technology company, announced the winners of its seventh Biopharma Innovation Cup. The winning team received €20,000 for its innovative idea around the role of Natural Killer (NK) cells in cancer immunology. The Biopharma Innovation Cup is designed to support the professional development of post-graduate students and to foster innovation from a promising new generation of academic talent.

BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Pfizer Inc. (NYSE:PFE) announced that the European Commission has approved BESPONSA® (inotuzumab ozogamicin) as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This indication includes treatment of adults with Philadelphia chromosome positive (Ph+) as well as Philadelphia chromosome negative (Ph-) relapsed or refractory B-cell precursor ALL.

Business

More Pharma News ...